熱門資訊> 正文
Replimune在黑色素瘤中的RP 1组合结果增加了30%
2024-06-07 00:05
- Replimune Group (NASDAQ:REPL) said that topline results of an analysis of a trial of RP1 plus Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) in melanoma patients who failed on a PD-1 inhibitor indicated one-third of them responded to the combination treatment.
- Patients enrolled in the IGNYTE trial had progressed while on a PD-1 inhibitor for at least 8 weeks.
- Results also showed durability with all responses lasting more than six months and median duration of response of more than 35 months.
- Replimune is up ~30% in early Thursday afternoon trading.
- The company plans to submit a Biologics License Application to the U.S. FDA in the second half of the year and enroll the first patients in the IGNITE-3 confirmatory trial in Q3.
More on Replimune Group
- Replimune: Continuing To Justify The Bear Thesis (For Now)
- Seeking Alpha’s Quant Rating on Replimune Group
- Historical earnings data for Replimune Group
- Financial information for Replimune Group
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
